A One Time CRISPR Infusion for Hereditary Angioedema Now Has a March Decision Date and No Advisory Panel

FDA accepted a priority review for lonvo-z, a one-time CRISPR treatment for hereditary angioedema, with a decision target of March 10, 2027.

Have A Referral?